2 completed, 2 terminated, 1 enrolling by invitation. 2 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Terminated 1 |
Follow golodirsen: new trials by email Literature Review of golodirsen trials Research Report on golodirsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] - Duchenne Muscular Dystrophy | Phase 4 | Terminated | Rare Disease Research, LLC | 2 | 2020-10-31 | 2026-04-03 |
| A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications. Amondys 45, Exondys 51, Vyondys 53 - Duchenne Muscular Dystrophy | Phase 2 | Completed | Kevin Flanigan | 3 | 2020-02-18 | 2023-10-26 |
| A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice Eteplirsen, Golodirsen, Casimersen - Duchenne Muscular Dystrophy | Enrolling by invitation | Sarepta Therapeutics, Inc. | 300 | 2019-01-07 | 2025-09-10 | |
| An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy Casimersen, Golodirsen - Duchenne Muscular Dystrophy | Phase 3 | Terminated | Sarepta Therapeutics, Inc. | 171 | 2018-08-02 | 2024-09-19 |
| Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) SRP-4045, SRP-4053, Placebo - Duchenne Muscular Dystrophy | Phase 3 | Completed | Sarepta Therapeutics, Inc. | 228 | 2016-09-28 | 2025-11-18 |
Muscular Dystrophy, Duchenne (5)
Sarepta Therapeutics, Inc. (3) · Kevin Flanigan (1) · Rare Disease Research, LLC (1)
United States (5) · Belgium (2) · Bulgaria (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Poland (2) · Spain (2) · Sweden (2) · United Kingdom (2) · Argentina (1) · Australia (1)
PMID 34105177, PMID 40098309, PMID 41961051
2015 (1), 2017 (1)